KPW
CTIC

Kore Private Wealth’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Kore Private Wealth’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33
Closed – – 1229
2020
Q2 		$0 Hold
33
– – ﹤0.01% 1334
2020
Q1 		$0 Hold
33
– – ﹤0.01% 1266
2019
Q4 		$0 Buy
+33
New +$31 ﹤0.01% 1104

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kore Private Wealth's CTIC Position: Q3 2020 in Review

Kore Private Wealth sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2020, closing a stake of 33 shares.

Kore Private Wealth first reported a position in CTIC in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 38 funds tracked by Wall St. Rank hold CTIC as of Q3 2020.

  • Kore Private Wealth reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2020 after selling out during the quarter.
  • Kore Private Wealth sold 33 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2020.
  • Kore Private Wealth first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2019 and held it in 3 quarters.
  • Kore Private Wealth's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q2 2020.
  • 38 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.